Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma

Official title: Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

Run by Indiana University · NCT07847073 · Data updated 2026-11-12

In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment13 (estimated)
SponsorIndiana University
Academic / other
Locations1 site (Bloomington, Indiana)
StatusRecruiting
StartedOctober 2026
Main results expectedJanuary 2028
Study endsJanuary 2028
Registry record updatedOctober 28, 2026
Trial IDNCT07847073 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older with open-angle glaucoma, suitable visual acuity, and not currently on conflicting therapies, who can complete a 12-month crossover protocol.

Probably not a fit

Patients who do not show differential retinal protection or who experience adverse effects may not benefit beyond standard IOP control.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, investigator-mmasked, crossover pilot trial comparing netarsudil (Rhopressa) and timolol in adults with open-angle glaucoma. Participants will use each medication for six months in random order, with regular visits to measure intraocular pressure and retinal structure. High-resolution AO-OCT imaging will track individual retinal ganglion cell layer changes over time to see if Rhopressa offers neuroprotection beyond pressure lowering. The study aims to determine if Rhopressa can reduce ganglion cell loss while maintaining similar IOP reduction to Timolol.

Why it matters

Potential benefit: If successful, Rhopressa could offer added protection of retinal nerve cells for glaucoma patients.

How similar studies have gone: Prior work suggests potential neuroprotective effects of ROCK inhibitors, but direct cell-level protection with clinical imaging has not been clearly demonstrated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All subjects will be 18 years of age or older
* Subjects must be diagnosed with open-angle glaucoma and have had an eye exam within the past year
* Subjects with glaucoma will have structural (optic nerve and retinal nerve fiber layer) and functional (visual field testing) defects consistent with the diagnosis of glaucoma
* Subjects will have a corrected acuity of 20/50 or better and be able to fixate
* Naïve to medication subjects or post washout IOP between 18 and 34 mmHg
* Spherical equivalent from +3 diopters to -6 diopters, with a cylinder of \<-3 diopters
* Subject is willing and able to comply with the protocol requirements and to remain in the study for its full duration, including all scheduled visits and follow-up assessments

Exclusion Criteria:

* Subjects with a known intolerance to netarsudil ophthalmic solution
* Subjects with a known intolerance to, or contraindication for, timolol maleate
* Any subject whom the investigator determines to be at unacceptable risk for the washout or believes is unlikely to complete the study
* Subjects with retinal disease or optic neuropathies other than glaucoma that, in the opinion of the investigator, could confound the study assessments or outcome
* Female subjects who are pregnant, breastfeeding, or of childbearing age who are not sterile or using an acceptable method of contraception during the study

Where it's running

  • Indiana University School Of Optometry
    Bloomington, Indiana, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.